

1

²
Name of Journal: *World Journal of Gastroenterology***Manuscript NO:**52599**Manuscript Type:** SYSTEMATIC REVIEWS**Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review**

Takumi Onoyama, Yohei Takeda, Taro Yamashita, Wataru Hamamoto, Yuri Sakamoto, Hiroki Koda, Soichiro Kawata, Kazuya Matsumoto, Hajime Isomoto

Abstract**BACKGROUND**

Programmed cell death-1 (PD-1) inhibitor has been indicated for many types of malignancies. However, these inhibitors also cause immune-related adverse events. Hepatobiliary disorder is a phenotype of immune-related adverse event affecting 0%–4.5% of patients treated with PD-1 inhibitors. Recent studies have reported PD-1 inhibitor-related sclerosing cholangitis (SC); however, the associated clinical and pathological features are unclear.

AIM

To evaluate the clinical and pathological features of PD-1 inhibitor-related SC

Match Overview

1	Internet 162 words crawled on 08-Nov-2017 link.springer.com	5%
2	Internet 27 words crawled on 29-Aug-2019 f6publishing.blob.core.windows.net	1%
3	Crossref 20 words Yoh Zen, Yen-Ying Chen, Yung-Ming Jeng, Hung-Wen Tsai, Matthew M Yeh. "Immune-related adverse reactions in the	1%
4	Internet 13 words crawled on 03-Jan-2020 www.thieme-connect.de	<1%
5	Internet 12 words crawled on 09-Oct-2018 www.whba1990.org	<1%
6	Internet 12 words crawled on 23-Jul-2019 bmcsurg.biomedcentral.com	<1%



Programmed cell death-1 inhibitor-related sclerosing cholangi



ALL

IMAGES

VIDEOS

关闭取词

12,800 Results

Any time ▼

[PDF] Peroral cholangioscopy of programmed cell death-1 ...

<https://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-0948-1271.pdf>

Peroral cholangioscopy of programmed cell death-1 inhibitor-related sclerosing cholangitis:

three case reports Programmed cell death-1 (PD-1) inhibitor therapy is indicated for many types of malignancies, but can lead to immune-related adverse events [1,2]. Recently, PD-1 inhibitor-related cholangitis and its clinical features, including peroral

Efficacy and Safety of Chemotherapy Following Anti-PD-1 ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543221>

May 01, 2019 · Immunotherapy targeting programmed cell death-1 (PD-1) signaling is becoming the standard of care for advanced gastric cancer. We herein report a patient with gastric adenocarcinoma with peritoneal dissemination who was treated with nab-paclitaxel and ramucirumab following nivolumab and developed sclerosing cholangitis.

Cited by: 1 Author: Masashi Kono, Toshiharu Sakurai, Kazuk...

Publish Year: 2019

Antiprogrammed Cell Death-1 Immunotherapy-Related ...

[https://aasidpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.30189@10.1002/\(ISSN\)1527...](https://aasidpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.30189@10.1002/(ISSN)1527...)

Jul 23, 2018 · He was receiving treatment of antiprogrammed cell death-1 (PD-1) immunotherapy with pembrolizumab (2.0 mg/kg) every 3 weeks for a malignant melanoma in his left heel. Computed tomography (CT) was performed before pembrolizumab treatment (Fig. 1 A) at the onset of cholangitis (Fig. 1 B), and 1 month after laboratory data returned to the ...

Cited by: 3 Author: Kohei Ogawa, Kenya Kamimura, Shuji Terai

Publish Year: 2019

A case of nivolumab-related cholangitis and literature ...

<https://link.springer.com/content/pdf/10.1007/s10637-017-0484-6.pdf>

Jun 20, 2017 · Anti-programmed cell death-1 (PD-1) monoclonal antibodies, such as nivolumab, used for the treatment of several tumors, can trigger effector T-cells against tumor- and self-antigens, leading to the occurrence of different immune-related adverse events. Among them, liver injuries are rare and usually transient. To date, only four cases of immune-related cholangitis in non-small cell lung cancer ...

Cited by: 9 Author: Francesco Gelsomino, Giovanni Vitale, A...

Publish Year: 2018



Programmed cell death-1 inhibitor-related sclerosing cholangi



ALL

IMAGES

VIDEOS

开启取词

12,800 Results

Any time ▾

[PDF] Peroral cholangioscopy of programmed cell death-1 ...

<https://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-0948-1271.pdf>

Peroral cholangioscopy of programmed cell death-1 inhibitor-related sclerosing cholangitis: three case reports Programmed cell death-1 (PD-1) inhibitor therapy is indicated for many types of malignancies, but can lead to immune-related adverse events [1,2]. Recently, PD-1 inhibitor-related cholangitis and its clinical features, including peroral

Efficacy and Safety of Chemotherapy Following Anti-PD-1 ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543221>

May 01, 2019 · Immunotherapy targeting programmed cell death-1 (PD-1) signaling is becoming the standard of care for advanced gastric cancer. We herein report a patient with gastric adenocarcinoma with peritoneal dissemination who was treated with nab-paclitaxel and ramucirumab following nivolumab and developed sclerosing cholangitis.

Cited by: 1

Author: Masashi Kono, Toshiharu Sakurai, Kazuk...

Publish Year: 2019

A case of nivolumab-related cholangitis and literature ...

<https://link.springer.com/content/pdf/10.1007/s10637-017-0484-6.pdf> ▾

Jun 20, 2017 · Anti-programmed cell death-1 (PD-1) monoclonal antibodies, such as nivolumab, used for the treatment of several tumors, can trigger effector T-cells against tumor- and self-antigens, leading to the occurrence of different immune-related adverse events. Among them, liver injuries are rare and usually transient. To date, only four cases of immune-related cholangitis in non-small cell lung cancer ...

Cited by: 9

Author: Francesco Gelsomino, Giovanni Vitale, A...

Publish Year: 2018

Antiprogrammed Cell Death-1 Immunotherapy-Related ...

[https://aasidpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.30189@10.1002/\(ISSN\)1527...](https://aasidpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.30189@10.1002/(ISSN)1527...)

Jul 23, 2018 · He was receiving treatment of antiprogrammed cell death-1 (PD-1) immunotherapy with pembrolizumab (2.0 mg/kg) every 3 weeks for a malignant melanoma in his left heel. Computed tomography (CT) was performed before pembrolizumab treatment (Fig. 1 A) at the onset of cholangitis (Fig. 1 B), and 1 month after laboratory data returned to the ...

Cited by: 3

Author: Kohei Ogawa, Kenya Kamimura, Shuji Terai

Publish Year: 2019